全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Tristan Struja , Alexander Kutz , Stefan Fischli ...
来源:[J].BMC Medicine(IF 6.679), 2017, Vol.15 (1)
摘要:Uncertainty about factors influencing the susceptibility and triggers for Graves’ disease persists, along with a wide variation in the response to anti-thyroid drugs, currently at approximately 50% of non-responders. The aim of this narrative review is to summarize immunolog...
作者:Ivan K. Chinn , Alice Y. Chan , Karin Chen ...
来源:[J].The Journal of Allergy and Clinical Immunology(IF 12.047), 2020, Vol.145 (1), pp.46-69
摘要:Genetic testing has become an integral component of the diagnostic evaluation of patients with suspected primary immunodeficiency diseases. Results of genetic testing can have a profound effect on clinical management decisions. Therefore clinical providers must demonstrate profic...
作者:Dimana Dimitrova , Juan Gea-Banacloche , Seth M. Steinberg ...
来源:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2020, Vol.26 (1), pp.94-106
摘要:ABSTRACT(#br)Allogeneic blood or marrow transplantation (BMT) is a potentially curative therapy for patients with primary immunodeficiency (PID). Safe and effective reduced-intensity conditioning (RIC) approaches that are associated with low toxicity, use alternative donors, and ...
作者:Kim Elsink , Joris M. van Montfrans , Mariëlle E. van Gijn ...
来源:[J].Clinical Immunology(IF 3.771), 2020, Vol.213
摘要:Abstract(#br)Background(#br)New, innovative, costly diagnostic methods for patients with primary immunodeficiencies (PID) demand upfront insight into their potential cost savings and added value for individual patients. As such, high quality, comparable economic evaluations are o...
作者:Lucy Duan , Eyal Grunebaum
来源:[J].Clinical Immunology(IF 3.771), 2018, Vol.194, pp.46-59
摘要:Abstract(#br)Primary Immunodeficiency disorders (PID) have been increasingly recognized in association with hematologic malignancies. To better appreciate this association, a systemic search of the Ovid MEDLINE database was performed with terms related of hematologic malignancies...
作者:Rohan Ameratunga
来源:[J].Allergy, Asthma & Clinical Immunology, 2017, Vol.13 (1)
摘要:Immunoglobulin therapy plays a critical role in the treatment of immunodeficiency disorders as well as autoimmune and inflammatory conditions. In immunodeficient patients, there has been controversy whether initial loading doses of intravenous (IVIG) should be based on actual bod...
作者:Fabian Hauck , Rebecca Voss , Christian Urban ...
来源:[J].The Journal of Allergy and Clinical Immunology(IF 12.047), 2018, Vol.141 (1), pp.59-68.e4
摘要:Malignancies occur with a higher incidence rate and manifest earlier in life in patients with primary immunodeficiency disorders (PIDs) than in the general population. However, no universal mechanism of malignancy predisposition in patients with PIDs has been determined. Despit...
作者:Mary A. Slatter , Kanchan Rao , Intan Juliana Abd Hamid ...
来源:[J].Biology of Blood and Marrow Transplantation(IF 3.94), 2018, Vol.24 (3), pp.529-536
摘要:Abstract(#br)We previously published results for 70 children who received conditioning with treosulfan and cyclophosphamide (n = 30) or fludarabine (n = 40) before undergoing hematopoietic stem cell transplantation (HSCT) for primary immunodeficiency (PID). Toxicity was lower and...
作者:Gholamreza Azizi , Reza Yazdani , Wiliam Rae ...
来源:[J].Autoimmunity Reviews(IF 7.975), 2018
摘要:Abstract(#br)Primary immunodeficiency diseases (PIDs) consist of a large group of genetic disorders that affect distinct components of the immune system. PID patients are susceptible to infection and non-infectious complications, particularly autoimmunity. A specific group of ...
作者:Baldassarre Martire , Chiara Azzari , Raffaele Badolato ...
来源:[J].Vaccine(IF 3.492), 2018, Vol.36 (24), pp.3541-3554
摘要:Abstract(#br)Infectious complications are a major cause of morbidity and mortality in patients with primary or secondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective healthcare measures mainly for these subjects. However immunocompro...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×